The use of Epstein-Barr virus-transformed B lymphocyte cell lines in a peptide-reconstitution assay: identification of CEA-related HLA-A*0301-restricted potential cytotoxic T-lymphocyte epitopes.

In the development of cytotoxic T lymphocyte (CTL)-mediated immunotherapy, the identification of CTL epitopes is of crucial importance. Binding of a peptide to major histocompatibility complex (MHC) class I molecules is one of the prerequisites for its function as a CTL epitope. We describe the technique, validation, and application of a simple cellular assay, intended for the screening of peptides for binding, that can be applied to any human leukocyte antigen (HLA) allele. Reconstitution of peptides in MHC class I molecules after elution by acid treatment was previously shown to be possible in specially engineered cell lines expressing only one type of MHC class I, and was applied for the HLA-A*0201 allele. We now report the optimal conditions for application of this type of binding assay to the HLA-A*0301 allele. The adaptations that were necessary to make the technique operational for HLA-A*0301 are shown in detail. These consisted of lowering the pH during acid treatment to 2.9 and lengthening the duration of elution to 90 s. Furthermore, immediate aspiration of eluted peptides appeared to be essential for this allele. We found also that the use of Epstein-Barr virus (EBV)-transformed B cell lines (B-LCL) yields results similar to those of the use of cell lines expressing only one specific MHC class I allele. Homozygosity for the desired HLA allele improves the sensitivity of the assay, but heterozygous cells can also be employed. Finally, we applied this technique to a search for HLA-A*0301 binding peptides derived from carcinoembryonic antigen (CEA). Of a set of 34 CEA-specific peptides that fit with a specified HLA-A*0301-binding motif, we identified a set of six peptides with high binding affinity to this allele. These peptides can be regarded as potential CTL epitopes.

[1]  M. Feltkamp,et al.  Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity. , 1994, Molecular immunology.

[2]  J. Sidney,et al.  Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. , 1994, Molecular immunology.

[3]  S. H. van der Burg,et al.  p53, a potential target for tumor-directed T cells. , 1994, Immunology letters.

[4]  A Sette,et al.  Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. , 1994, Journal of immunology.

[5]  A Sette,et al.  Definition of specific peptide motifs for four major HLA-A alleles. , 1994, Journal of immunology.

[6]  A Sette,et al.  Naturally processed peptides longer than nine amino acid residues bind to the class I MHC molecule HLA-A2.1 with high affinity and in different conformations. , 1994, Journal of immunology.

[7]  M. Lotze,et al.  Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2. , 1994, Human immunology.

[8]  V. Engelhard.  Structure of peptides associated with MHC class I molecules. , 1994, Current opinion in immunology.

[9]  J. Sidney,et al.  Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules , 1993, Cell.

[10]  S. H. van der Burg,et al.  In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53 , 1993, European journal of immunology.

[11]  S. H. van der Burg,et al.  Identification of peptide sequences that potentially trigger HLA‐A2.1‐restricted cytotoxic T lymphocytes , 1993, European journal of immunology.

[12]  K. Parker,et al.  Endogenous peptides bound to HLA-A3 possess a specific combination of anchor residues that permit identification of potential antigenic peptides. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[13]  T. Elliott,et al.  A method to quantify binding of unlabeled peptides to class I MHC molecules and detect their allele specificity. , 1993, Journal of immunological methods.

[14]  Klas Kärre,et al.  Assessment of major histocompatibility complex class I interaction with Epstein‐Barr virus and human immunodeficiency virus peptides by elevation of membrane H‐2 and HLA in peptide loading‐deficient cells , 1992, European journal of immunology.

[15]  C. Melief,et al.  Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. , 1992, Advances in cancer research.

[16]  T. Boon,et al.  Recognition of tumor-associated antigens by T lymphocytes: from basic concepts to new approaches. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  A. Belldegrun,et al.  Autologous Tumor-Specific Cytotoxicity of Tumor-Infiltrating Lymphocytes Derived from Human Renal Cell Carcinoma , 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[18]  Timothy E. Elliott,et al.  The binding affinity and dissociation rates of peptides for class I major histocompatibility complex molecules , 1991, European journal of immunology.

[19]  V. Reyes,et al.  Binding of radioiodinated influenza virus peptides to class I MHC molecules and to other cellular proteins as analyzed by gel filtration and photoaffinity labeling. , 1991, Molecular immunology.

[20]  P. Greenberg.  Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. , 1991, Advances in immunology.

[21]  F. Grunert,et al.  Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives , 1991, Journal of clinical laboratory analysis.

[22]  K. Isselbacher,et al.  Epithelial glycoprotein is a member of a family of epithelial cell surface antigens homologous to nidogen, a matrix adhesion protein. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. Young,et al.  Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[24]  B. Guy,et al.  An antigenic peptide of the HIV‐1 NEF protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA‐B , 1989, European journal of immunology.

[25]  R. Offringa,et al.  Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes , 1989, Cell.

[26]  Abraham Fuks,et al.  Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule , 1989, Cell.

[27]  C. Stanners,et al.  Studies on the control of gene expression of the carcinoembryonic antigen family in human tissue. , 1989, Cancer research.

[28]  Y. Ikehara,et al.  Active production and membrane anchoring of carcinoembryonic antigen observed in normal colon mucosa. , 1988, Cancer letters.

[29]  K Kumagai,et al.  A simple method to eliminate the antigenicity of surface class I MHC molecules from the membrane of viable cells by acid treatment at pH 3. , 1987, Journal of immunological methods.

[30]  P. Cresswell,et al.  Impaired assembly and transport of HLA‐A and ‐B antigens in a mutant TxB cell hybrid. , 1986, The EMBO journal.

[31]  K. Yoshiko,et al.  Immunological characterization and structural studies of normal fecal antigen-1 related to carcinoembryonic antigen. , 1982 .

[32]  P. Cresswell,et al.  Monoclonal antibody to HLA-A3. , 1982, Hybridoma.

[33]  P. Parham,et al.  Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. , 1981, Human immunology.